中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (8): 580-583.doi: 10.12144/zgmfskin202608580

• 临床研究 • 上一篇    下一篇

托法替布治疗原发性皮肤淀粉样变三例疗效评价

施林林1,施辛2   

  1. 1 南通大学杏林学院附属惠山医院皮肤科，无锡市惠山区人民医院皮肤科，江苏无锡，214187；2 苏州大学附属第二医院皮肤科，江苏苏州，215004
  • 出版日期:2026-08-15 发布日期:2026-08-03

Clinical observation of tofacitinib in the treatment of primary cutaneous amyloidosis in 3 cases

SHI Linlin1, SHI Xin2   

  1. 1 Department of Dermatology, Huishan Hospital Affiliated to Xinglin College of Nantong University, Huishan District People's Hospital of Wuxi, Wuxi 214187, China; 2 Department of Dermatology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China
  • Online:2026-08-15 Published:2026-08-03

PDF (PC)

43

摘要： 原发性皮肤淀粉样变（primary cutaneous amyloidosis, PCA）是一种以真皮乳头层淀粉样蛋白沉积为特征的慢性瘙痒性皮肤病，传统治疗在难治性病例中疗效欠佳，本研究纳入3例PCA患者，予口服托法替布治疗，并采用皮肤症状评分和不良事件监测评估疗效与安全性，结果显示托法替布可迅速缓解瘙痒，并持续促进皮损消退，患者耐受性良好，不良反应可控。托法替布在难治性PCA中具有潜在的临床应用价值。

关键词: 原发性皮肤淀粉样变性, 托法替布, JAK抑制剂

Abstract: Primary cutaneous amyloidosis (PCA) is a chronic pruritic dermatosis characterized by deposition of amyloid protein in the dermal papillae. Conventional therapies yield unsatisfactory efficacy for refractory cases. In this study, three patients with PCA were treated with oral tofacitinib, and the efficacy and safety were evaluated via cutaneous lesion scoring and adverse event monitoring. The results demonstrated that tofacitinib rapidly relieved pruritus and continuously promoted regression of skin lesions with favourable patient tolerance and manageable adverse reactions. In conclusion, tofacitinib possesses potential clinical application value for refractory PCA.

Key words: primary cutaneous amyloidosis, tofacitinib, JAK inhibitor